Streetbeat News

Products Services

JEPI

MSFT

SPYI

The article discusses the NEOS S&P 500 High Income ETF (SPYI) as a reliable source of monthly income during unpredictable market conditions. It compares SPYI with the JPMorgan Equity Premium Income ETF (JEPI), highlighting SPYI's superior performance and tax efficiency. SPYI invests in all S&P 500 constituents and uses out-of-the-money covered call options to generate income, offering a consistent monthly distribution. In contrast, JEPI's performance and income distribution have been less stable.

Portfolio Pulse from Austin Hankwitz

September 05, 2024 | 2:16 pm

SIRI

TM

Toyota and Lexus have joined SiriusXM's new three-year Extended Service Subscription program, allowing dealerships to offer extended SiriusXM services with new vehicle purchases. This program aims to enhance customer value and flexibility in payment options.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 2:06 pm

MSFT

OpenAI is considering high-priced subscriptions for its upcoming AI models, Strawberry and Orion, with potential prices up to $2,000 per month. This pricing strategy could impact competitors like Google and Anthropic.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 2:02 pm

AAPL

PYPL

PayPal is integrating its debit card with Apple Pay and offering cashback rewards to enter the U.S. point-of-sale market. This strategic move aims to capture in-person purchases, supported by a significant marketing investment.

Portfolio Pulse from Benzinga Neuro

September 05, 2024 | 1:54 pm

BMRN

BioMarin Pharmaceutical Inc (NASDAQ:BMRN) aims for $4 billion in revenue by 2027, focusing on three business units: skeletal conditions, enzyme therapies, and Roctavian. The company is implementing a $500 million cost transformation program to achieve a 40% operating margin by 2026. BioMarin's pipeline includes promising programs like Voxzogo, which could become a $5 billion opportunity. The company plans to launch two new products by 2027 and has updated its Roctavian strategy to focus on the U.S., Germany, and Italy.

Portfolio Pulse from Vandana Singh

September 05, 2024 | 1:51 pm

LLY

Eli Lilly's once-weekly insulin efsitora alfa shows non-inferior blood sugar reduction compared to daily insulins in long-term trials. The QWINT-1 and QWINT-3 trials met their primary endpoints, demonstrating similar efficacy to daily insulin glargine and degludec. Despite positive results, LLY stock is down 2.25%.

Portfolio Pulse from Vandana Singh

September 05, 2024 | 1:47 pm

CODX

Co-Diagnostics shares rose after the company announced successful in silico analysis of its Co-Dx Logix Smart Mpox RUO test, confirming its effectiveness against recent mpox strains, including clade 1b.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 1:33 pm

CGC

CURLF

Canopy Growth's subsidiary in Poland is withdrawing its popular medical marijuana strain Penelope due to aging genetics and quality concerns. The company plans to introduce new strains with similar profiles. Meanwhile, Poland's medical marijuana market is booming, with a significant increase in prescriptions and support for decriminalization.

Portfolio Pulse from Nina Zdinjak

September 05, 2024 | 1:32 pm

CODX

Co-Diagnostics has completed an updated analysis of its 2-Gene Mpox RUO Test, confirming that the test retains full reactivity against Mpox strains, including Clade 1b, circulating over the past year.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 1:32 pm

AIQ

AVEM

BABA

Alibaba's Taobao and Tmall platforms now accept WeChat payments, aiming to expand market share in China amid intense competition. This move could help Alibaba grow in less developed regions. Alibaba's stock has declined 13% over the past year. The company also launched a new digital technology company and reported a 4% revenue growth in Q1, missing analyst expectations.

Portfolio Pulse from Anusuya Lahiri

September 05, 2024 | 1:22 pm